Day: August 20, 2025

Connected brands, including Connected Cannabis, AlienLabs and Smoken Promises branded products, to be distributed through the ENTOURAGE wholesale network and FLUENT retail stores NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) — FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) (“FLUENT” or the “Company”), today announced the commencement of operations at its new 68,000+ square-foot indoor cultivation facility in Buffalo, New York. This facility doubles FLUENT’s New York cultivation capacity and further strengthens its premium wholesale portfolio across the state. Alongside this expansion, FLUENT has entered into an exclusive partnership (the “Partnership”) with Connected New York Inc. (“Connected”), a part of the Connected International Inc. family and the California-based industry leader recognized for its award-winning brands, cutting-edge...

While others remain stuck in pilots, Rezolve Ai has already proven that:AI delivers measurable value Vertical focus beats generic models every time Real contracts, real revenues, and global growth set Rezolve Ai apartNEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) — As questions emerge over whether artificial intelligence is truly delivering returns, Rezolve Ai (NASDAQ: RZLV), believes it stands as proof that AI is capable of transforming industries when built with purpose. Focused on retail and commerce, Rezolve Ai’s technology is creating measurable value for enterprises worldwide. The Rezolve Ai Advantage Rezolve Ai has already achieved what others are still trying to figure out:AI that delivers measurable value. A vertical focus that consistently beats generic models. Real contracts, real revenues, and real global growth.Rezolve...

MINNEAPOLIS, Aug. 20, 2025 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD), announced the addition of 85 cardiovascular centers and data sources, expanding its Cardiovascular network thereby positioning OneMedNet as one of the largest providers for Cardiovascular Real-World data. Cardiovascular diseases (CVDs) remain the world’s leading cause of death, responsible for approximately 19.8 million deaths in 2022, accounting for roughly 32% of all global mortality1. Economically, the burden is staggering: CVD drives an estimated $320 billion annually in the United States alone, and more than $1 trillion globally each year in direct healthcare costs and lost productivity2. Such pervasive health and financial pressures make OneMedNet’s enriched multimodal...

Hotel101-Phnom Penh Cambodia is set to have approx 700 rooms with 30 floors to rise in a prime 2,033 square meters commercial land at Tonle Bassac, a vibrant riverfront economic and cultural hub near the popular upscale BKK District Hotel101-Sihanoukville Cambodia is set to have approx 680 rooms to rise in a prime 4,623 square meters commercial land right beside the proposed international convention and exhibition center within the master-planned Bay of Lights coastal development Hotel101-Phnom Penh and Hotel101-Sihanoukville projects in Cambodia are expected to generate $109.55 Million USD in sales revenue Hotel101’s entry to the Cambodian market to add to the current hospitality offerings that are now already operating in Cambodia which includes global hotel brands such as Hyatt, Rosewood, Raffles and Shangri-La Cambodia is seen...

Today, Landsbankinn concluded the sale of floating rate senior preferred bonds in the amount of NOK 400 million with a maturity of three years. The bonds were priced at a spread of 87bps over 3-month NIBOR. The bonds will be issued under the bank’s EMTN programme and expected to be admitted to trading on Euronext Dublin as of 28 August 2025. SEB acted as a dealer on the transaction.

Pre-Treatment with blarcamesine entirely prevented Abeta-induced cognitive decline Confirmed significant biomarker-response in hippocampus NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported a peer-reviewed publication in the journal Neuroscience Letters, titled “Prevention of memory impairment and hippocampal injury with blarcamesine in an Alzheimer’s disease model.”1 This study shows that a pre-treatment with blarcamesine prevented Amyloid beta-induced memory impairment...